This study will evaluate the safety and efficacy of 2 weeks of topical KD7040 versus placebo
in the treatment of postherpetic neuralgia.
- Male or female subjects ages 18-85 years
- Previous diagnosis of Shingles (Herpes Zoster) with pain persisting for at least 3
months, but not longer than 5 years, after healing of rash
- Subject with intact skin in the targeted treatment area
- Female subjects of childbearing potential must have a negative serum pregnancy test
at screening, a negative urine human chorionic gonadotropin (hCG) test prior to
randomization, and must use medically acceptable methods of birth control. All
subjects must agree to take every precaution to ensure that pregnancy will not occur
during the study.
- Subject must be willing and able to complete screening and study procedures as
described int he protocol.
- Subject must voluntarily provide written Informed Consent prior to participation.
- Subjects with known hypersensitivity to KD7040 or methylparaben, or previous exposure
- Subjects pregnant, nursing or planning to become pregnant.
- Subjects who are immunocompromised or have clinically significant hematological
- Subjects with system dermatological conditions (e.g., psoriasis, atopic dermatitis)
or impaired wound healing.
- Subjects who have had local anesthetic nerve blocks within 48 hours of study entry.
- Subjects having other sever pain which may confound assessment of PHN.
- Subjects who have serious, unstable, or clinically significant medical or
psychological conditions, which, in the opinion of the Investigator(s) would
compromise the subjects' participation in the study.